| __timestamp | Amicus Therapeutics, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 2908166 |
| Thursday, January 1, 2015 | 47269000 | 6356782 |
| Friday, January 1, 2016 | 71151000 | 4303743 |
| Sunday, January 1, 2017 | 88671000 | 10463151 |
| Monday, January 1, 2018 | 127200000 | 22639184 |
| Tuesday, January 1, 2019 | 169861000 | 67046483 |
| Wednesday, January 1, 2020 | 156407000 | 139401000 |
| Friday, January 1, 2021 | 192710000 | 176771000 |
| Saturday, January 1, 2022 | 213041000 | 277163000 |
| Sunday, January 1, 2023 | 275270000 | 500815000 |
Infusing magic into the data realm
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Apellis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting SG&A spending patterns. From 2014 to 2023, Amicus saw a steady increase in SG&A expenses, growing by approximately 1,230%, reflecting its strategic investments in market expansion and operational efficiency. Meanwhile, Apellis exhibited a more dramatic rise, with SG&A expenses skyrocketing by over 17,000% during the same period, indicating aggressive scaling and market penetration efforts. By 2023, Apellis's SG&A expenses were nearly double those of Amicus, highlighting its rapid growth trajectory. These trends underscore the dynamic nature of the biotech industry, where financial strategies are as crucial as scientific innovation.
Johnson & Johnson or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sanofi and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Mesoblast Limited
Apellis Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Veracyte, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
ACADIA Pharmaceuticals Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Galapagos NV